Sign in

    Thomas Walsh

    Research Analyst at Barclays

    Thomas Walsh is an analyst at Barclays specializing in equity research, with a focus on covering major publicly traded companies in sectors such as financial services, consumer goods, and technology. He provides coverage for industry leaders, delivering investment recommendations that have demonstrated solid performance benchmarks, including above-average success rates and returns reported on platforms like TipRanks. Walsh began his career in financial analysis in the early 2010s, with previous experience at other investment firms before joining Barclays as a full-time analyst several years ago. He holds FINRA registration and maintains multiple securities licenses, reflecting his professional credentials and adherence to regulatory standards.

    Thomas Walsh's questions to agilon health (AGL) leadership

    Thomas Walsh's questions to agilon health (AGL) leadership • Q1 2025

    Question

    Thomas Walsh, on for Andrew Mok, noted that Q2 EBITDA guidance implies different seasonality than in prior years and asked for color on the expected trajectory of medical margin and EBITDA throughout 2025.

    Answer

    CFO Jeffrey Schwaneke explained that direct comparisons to prior years are difficult due to significant prior period development that occurred in Q3 of last year. He stated the current budget is built on an incurred basis, which restates the timing of those costs and alters the seasonal appearance. He advised to expect a normal progression with higher profitability in early quarters and the highest medical costs in Q4.

    Ask Fintool Equity Research AI